The Latest Breaking News from CDMO

From CDMO to aerospace: How Vikas Khemani finds India’s next big themes

Now, as Carnelian has ventured into mutual fund business by launching a small-cap fund with a ₹5,000 crore cap, Khemani is focusing on manufacturing, financials and IT while warning investors against confusing market capitalisation with valuation. In an interview, he explains how the fund plans to manage size, assess expensive…

The Economic Times · 7h ago

Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside

Nuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upside from the current market price. The brokerage expects the drugmaker’s shift from its traditional anti-retroviral (ARV) business towards contract development and manufacturing (CDMO) to drive its…

The Economic Times · Oct 16

Nifty valuations near post-Covid lows. Alchemy Capital’s Alok Agarwal explains what investors should buy now

Nifty valuations have reset sharply from 2024 levels and are now near post-Covid lows, says Alchemy Capital’s Alok Agarwal. He sees the next phase of market growth broadening beyond large caps. Mid- and small-caps, AI infrastructure, healthcare, manufacturing and select defence companies offer opportunities, while global yields and FPI flows…

The Economic Times · Oct 2

Akums Drugs shares rally 9% hit 52-week high after Q1 results; stock up 67% YTD

Akums Drugs shares rose sharply on Monday to hit a 52-week high after the company reported strong Q1 FY27 results. Revenue rose 13.9% year-on-year, while profit increased 55%. EBITDA grew 35.4%, supported by strong performance in its CDMO business. The stock has gained 67% so far this year.

The Economic Times · Aug 10

Navin Fluorine shares surge 8% after Q1 profit more than doubles. Should you buy, sell or hold?

Navin Fluorine shares surged nearly 8% after the company posted a strong Q1FY27 performance, with profit more than doubling and revenue rising 44% YoY. Elara Securities retained its 'Buy' rating and Rs 9,158 target, citing robust growth in refrigerants, specialty chemicals and CDMO, along with a strong expansion pipeline that…

The Economic Times · Aug 6

India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like Sai Life Sciences are investing heavily in capacity, anticipating a surge in demand. While regulatory processes mean benefits will be gradual, this supply-chain realignment presents a landmark opportunity for India's CDMO sector,…

The Economic Times · Jun 25

Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China

WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing in the development and…

AAP · Jun 3

AI-linked hiring in CDMO industry jumps nearly 3-fold in 2 years: Report

Artificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI skills in CDMOs will nearly triple between 2023 and 2025. This reflects a significant shift towards automation and advanced capabilities. Manufacturing and operations remain key areas. However, a talent gap is…

The Economic Times · May 28

AGC Biologics to Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance

HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc…

AAP · May 26

Deepa Jewellers, Cotec Healthcare receive Sebi approval for IPOs

Deepa Jewellers, a B2B hallmarked gold jewellery processor based in Hyderabad, and Cotec Healthcare, a pharmaceutical CDMO, both received SEBI approval for their IPOs. Deepa's IPO includes a Rs 250 crore fresh issue and an offer for sale by promoters.

The Economic Times · May 22